Oct. 27 (Bloomberg) -- Elan Elan Corp. said “based on the strong performance of Tysabri year-to-date, we are re-affirming our full year guidance and now expect revenues from our BioNeurology business to exceed $1 billion this year.”

To contact the editor responsible for this story: Dara Doyle at ddoyle1@bloomberg.net